{"entity_poly": {"nstd_linkage": "no", "nstd_monomer": "no", "pdbx_seq_one_letter_code": "MKLFAQGTSLDLSHPHVMGILNVTPDSFSDGGTHNSLIDAVKHANLMINAGATIIDVGGESTRPGAAEVSVEEELQRVIPVVEAIAQRFEVWISVDTSKPEVIRESAKVGAHIINDIRSLSEPGALEAAAETGLPVCLMHMQGNPKTMQEAPKYDDVFAEVNRYFIEQIARCEQAGIAKEKLLLDPGFGFGKNLSHNYSLLARLAEFHHFNLPLLVGMSRKSMIGQLLNVGPSERLSGSLACAVIAAMQGAHIIRVHDVKETVEAMRVVEATLSAKENKRYE", "pdbx_seq_one_letter_code_can": "MKLFAQGTSLDLSHPHVMGILNVTPDSFSDGGTHNSLIDAVKHANLMINAGATIIDVGGESTRPGAAEVSVEEELQRVIPVVEAIAQRFEVWISVDTSKPEVIRESAKVGAHIINDIRSLSEPGALEAAAETGLPVCLMHMQGNPKTMQEAPKYDDVFAEVNRYFIEQIARCEQAGIAKEKLLLDPGFGFGKNLSHNYSLLARLAEFHHFNLPLLVGMSRKSMIGQLLNVGPSERLSGSLACAVIAAMQGAHIIRVHDVKETVEAMRVVEATLSAKENKRYE", "pdbx_strand_id": "A", "rcsb_artifact_monomer_count": 0, "rcsb_conflict_count": 0, "rcsb_deletion_count": 0, "rcsb_entity_polymer_type": "Protein", "rcsb_insertion_count": 0, "rcsb_mutation_count": 0, "rcsb_non_std_monomer_count": 0, "rcsb_sample_sequence_length": 282, "type": "polypeptide(L)"}, "entity_src_nat": [{"genus": "Escherichia", "pdbx_alt_source_flag": "sample", "pdbx_ncbi_taxonomy_id": "562", "pdbx_organism_scientific": "Escherichia coli", "pdbx_src_id": 1}], "rcsb_cluster_flexibility": {"avg_rmsd": 0.664, "label": "Low", "link": "http://pdbflex.org/cluster.html#!/1aj0A/110/1aj0A", "max_rmsd": 1.175, "provenance_code": "PDBFlex"}, "rcsb_cluster_membership": [{"cluster_id": 3858, "identity": 100}, {"cluster_id": 4785, "identity": 95}, {"cluster_id": 4718, "identity": 90}, {"cluster_id": 4939, "identity": 70}, {"cluster_id": 5928, "identity": 50}, {"cluster_id": 4592, "identity": 30}], "rcsb_entity_source_organism": [{"ncbi_common_names": ["Bacillus coli", "Bacterium coli", "Bacterium coli commune", "E. coli", "Enterococcus coli", "Escherichia/Shigella coli"], "ncbi_parent_scientific_name": "Bacteria", "ncbi_scientific_name": "Escherichia coli", "ncbi_taxonomy_id": 562, "pdbx_src_id": 1, "provenance_source": "Primary Data", "scientific_name": "Escherichia coli", "source_type": "natural", "taxonomy_lineage": [{"depth": 1, "id": "131567", "name": "cellular organisms"}, {"depth": 1, "id": "131567", "name": "biota"}, {"depth": 2, "id": "2", "name": "Bacteria"}, {"depth": 2, "id": "2", "name": "Bacteria (ex Cavalier-Smith 1987)"}, {"depth": 2, "id": "2", "name": "Bacteria Woese et al. 2024"}, {"depth": 2, "id": "2", "name": "Bacteriobiota"}, {"depth": 2, "id": "2", "name": "bacteria"}, {"depth": 2, "id": "2", "name": "eubacteria"}, {"depth": 3, "id": "3379134", "name": "Pseudomonadati"}, {"depth": 4, "id": "1224", "name": "Pseudomonadota"}, {"depth": 4, "id": "1224", "name": "\"Alphaproteobacteriota\" Whitman et al. 2018"}, {"depth": 4, "id": "1224", "name": "Alphaproteobacteriota"}, {"depth": 4, "id": "1224", "name": "Proteobacteria"}, {"depth": 4, "id": "1224", "name": "Proteobacteriota"}, {"depth": 4, "id": "1224", "name": "proteobacteria"}, {"depth": 4, "id": "1224", "name": "purple photosynthetic bacteria and relatives"}, {"depth": 5, "id": "1236", "name": "Gammaproteobacteria"}, {"depth": 5, "id": "1236", "name": "Proteobacteria gamma subdivision"}, {"depth": 5, "id": "1236", "name": "Pseudomonadia"}, {"depth": 5, "id": "1236", "name": "Purple bacteria, gamma subdivision"}, {"depth": 5, "id": "1236", "name": "g-proteobacteria"}, {"depth": 5, "id": "1236", "name": "gamma proteobacteria"}, {"depth": 5, "id": "1236", "name": "gamma subdivision"}, {"depth": 5, "id": "1236", "name": "gamma subgroup"}, {"depth": 6, "id": "91347", "name": "Enterobacterales"}, {"depth": 6, "id": "91347", "name": "Enterobacteriaceae and related endosymbionts"}, {"depth": 6, "id": "91347", "name": "Enterobacteriaceae group"}, {"depth": 6, "id": "91347", "name": "Enterobacteriales"}, {"depth": 7, "id": "543", "name": "Enterobacteriaceae"}, {"depth": 7, "id": "543", "name": "Enterobacteraceae"}, {"depth": 7, "id": "543", "name": "enterobacteria"}, {"depth": 8, "id": "561", "name": "Escherichia"}, {"depth": 9, "id": "562", "name": "Escherichia coli"}, {"depth": 9, "id": "562", "name": "Bacillus coli"}, {"depth": 9, "id": "562", "name": "Bacterium coli"}, {"depth": 9, "id": "562", "name": "Bacterium coli commune"}, {"depth": 9, "id": "562", "name": "E. coli"}, {"depth": 9, "id": "562", "name": "Enterococcus coli"}, {"depth": 9, "id": "562", "name": "Escherichia/Shigella coli"}]}], "rcsb_genomic_lineage": [{"depth": 0, "id": "511145", "name": "Escherichia coli str. K-12 substr. MG1655"}, {"depth": 0, "id": "621", "name": "Shigella boydii"}, {"depth": 0, "id": "622", "name": "Shigella dysenteriae"}, {"depth": 0, "id": "624", "name": "Shigella sonnei"}, {"depth": 0, "id": "564", "name": "Escherichia fergusonii"}, {"depth": 1, "id": "622:dihydropteroate_synthase", "name": "dihydropteroate synthase"}, {"depth": 1, "id": "624:dihydropteroate_synthase", "name": "dihydropteroate synthase"}, {"depth": 1, "id": "564:dihydropteroate_synthase", "name": "dihydropteroate synthase"}, {"depth": 1, "id": "511145:dihydropteroate_synthase", "name": "dihydropteroate synthase"}, {"depth": 1, "id": "621:dihydropteroate_synthase", "name": "dihydropteroate synthase"}], "rcsb_polymer_entity": {"formula_weight": 30.652, "pdbx_description": "DIHYDROPTEROATE SYNTHASE", "pdbx_ec": "2.5.1.15", "pdbx_number_of_molecules": 1, "rcsb_multiple_source_flag": "N", "rcsb_source_part_count": 1, "rcsb_source_taxonomy_count": 1, "src_method": "nat", "rcsb_ec_lineage": [{"depth": 1, "id": "2", "name": "Transferases"}, {"depth": 2, "id": "2.5", "name": "Transferring alkyl or aryl groups, other than methyl groups"}, {"depth": 3, "id": "2.5.1", "name": "Transferring alkyl or aryl groups, other than methyl groups (only sub-subclass identified to date)"}, {"depth": 4, "id": "2.5.1.15", "name": "dihydropteroate synthase"}], "rcsb_macromolecular_names_combined": [{"name": "DIHYDROPTEROATE SYNTHASE", "provenance_code": "ECO:0000304", "provenance_source": "PDB Preferred Name"}, {"name": "DHPS", "provenance_code": "ECO:0000303", "provenance_source": "PDB Synonym"}], "rcsb_enzyme_class_combined": [{"depth": 4, "ec": "2.5.1.15", "provenance_source": "PDB Primary Data"}], "rcsb_polymer_name_combined": {"names": ["Dihydropteroate synthase"], "provenance_source": "UniProt Name"}}, "rcsb_polymer_entity_align": [{"provenance_source": "SIFTS", "reference_database_accession": "P0AC13", "reference_database_name": "UniProt", "aligned_regions": [{"entity_beg_seq_id": 1, "length": 282, "ref_beg_seq_id": 1}]}], "rcsb_polymer_entity_annotation": [{"annotation_id": "PF00809", "assignment_version": "34.0", "name": "Pterin binding enzyme (Pterin_bind)", "provenance_source": "Pfam", "type": "Pfam"}, {"annotation_id": "GO:0005829", "name": "cytosol", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0110165", "name": "cellular anatomical structure"}, {"id": "GO:0005575", "name": "cellular_component"}, {"id": "GO:0005622", "name": "intracellular anatomical structure"}, {"id": "GO:0005737", "name": "cytoplasm"}, {"id": "GO:0005829", "name": "cytosol"}]}, {"annotation_id": "GO:0009410", "name": "response to xenobiotic stimulus", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0050896", "name": "response to stimulus"}, {"id": "GO:0042221", "name": "response to chemical"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0009410", "name": "response to xenobiotic stimulus"}]}, {"annotation_id": "GO:0046656", "name": "folic acid biosynthetic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0043436", "name": "oxoacid metabolic process"}, {"id": "GO:0042398", "name": "modified amino acid biosynthetic process"}, {"id": "GO:0009110", "name": "vitamin biosynthetic process"}, {"id": "GO:0006082", "name": "organic acid metabolic process"}, {"id": "GO:0016053", "name": "organic acid biosynthetic process"}, {"id": "GO:0046394", "name": "carboxylic acid biosynthetic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0044281", "name": "small molecule metabolic process"}, {"id": "GO:0043603", "name": "amide metabolic process"}, {"id": "GO:0046655", "name": "folic acid metabolic process"}, {"id": "GO:0043650", "name": "dicarboxylic acid biosynthetic process"}, {"id": "GO:0046656", "name": "folic acid biosynthetic process"}, {"id": "GO:0009396", "name": "folic acid-containing compound biosynthetic process"}, {"id": "GO:0042364", "name": "water-soluble vitamin biosynthetic process"}, {"id": "GO:0044283", "name": "small molecule biosynthetic process"}, {"id": "GO:0043648", "name": "dicarboxylic acid metabolic process"}, {"id": "GO:0006575", "name": "modified amino acid metabolic process"}, {"id": "GO:0019752", "name": "carboxylic acid metabolic process"}, {"id": "GO:0043604", "name": "amide biosynthetic process"}, {"id": "GO:0006766", "name": "vitamin metabolic process"}, {"id": "GO:0009058", "name": "biosynthetic process"}, {"id": "GO:0006760", "name": "folic acid-containing compound metabolic process"}, {"id": "GO:0042559", "name": "pteridine-containing compound biosynthetic process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0042558", "name": "pteridine-containing compound metabolic process"}]}, {"annotation_id": "IPR011005", "name": "Dihydropteroate synthase-like superfamily", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"id": "IPR011005", "name": "Dihydropteroate synthase-like superfamily"}]}, {"annotation_id": "GO:0004156", "name": "dihydropteroate synthase activity", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0004156", "name": "dihydropteroate synthase activity"}, {"id": "GO:0016740", "name": "transferase activity"}, {"id": "GO:0016765", "name": "transferase activity, transferring alkyl or aryl (other than methyl) groups"}, {"id": "GO:0003824", "name": "catalytic activity"}, {"id": "GO:0003674", "name": "molecular_function"}]}, {"annotation_id": "GO:0005737", "name": "cytoplasm", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0110165", "name": "cellular anatomical structure"}, {"id": "GO:0005575", "name": "cellular_component"}, {"id": "GO:0005622", "name": "intracellular anatomical structure"}, {"id": "GO:0005737", "name": "cytoplasm"}]}, {"annotation_id": "GO:0046654", "name": "tetrahydrofolate biosynthetic process", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0009396", "name": "folic acid-containing compound biosynthetic process"}, {"id": "GO:0042398", "name": "modified amino acid biosynthetic process"}, {"id": "GO:0006575", "name": "modified amino acid metabolic process"}, {"id": "GO:0009058", "name": "biosynthetic process"}, {"id": "GO:0006760", "name": "folic acid-containing compound metabolic process"}, {"id": "GO:0042559", "name": "pteridine-containing compound biosynthetic process"}, {"id": "GO:0008150", "name": "biological_process"}, {"id": "GO:0008152", "name": "metabolic process"}, {"id": "GO:0009987", "name": "cellular process"}, {"id": "GO:0046654", "name": "tetrahydrofolate biosynthetic process"}, {"id": "GO:0042558", "name": "pteridine-containing compound metabolic process"}, {"id": "GO:0046653", "name": "tetrahydrofolate metabolic process"}]}, {"annotation_id": "IPR045031", "name": "Dihydropteroate synthase-like", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"depth": 1, "id": "IPR045031", "name": "Dihydropteroate synthase-like"}]}, {"annotation_id": "IPR006390", "name": "Dihydropteroate synthase domain", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"depth": 2, "id": "IPR006390", "name": "Dihydropteroate synthase domain"}, {"depth": 1, "id": "IPR000489", "name": "Pterin-binding domain"}]}, {"annotation_id": "GO:0046872", "name": "metal ion binding", "provenance_source": "UNIPROT", "type": "GO", "annotation_lineage": [{"id": "GO:0043169", "name": "cation binding"}, {"id": "GO:0043167", "name": "ion binding"}, {"id": "GO:0005488", "name": "binding"}, {"id": "GO:0003674", "name": "molecular_function"}, {"id": "GO:0046872", "name": "metal ion binding"}, {"id": "GO:0036094", "name": "small molecule binding"}]}, {"annotation_id": "IPR000489", "name": "Pterin-binding domain", "provenance_source": "UNIPROT", "type": "InterPro", "annotation_lineage": [{"depth": 1, "id": "IPR000489", "name": "Pterin-binding domain"}]}], "rcsb_polymer_entity_container_identifiers": {"asym_ids": ["A"], "auth_asym_ids": ["A"], "chem_comp_monomers": ["ALA", "ARG", "ASN", "ASP", "CYS", "GLN", "GLU", "GLY", "HIS", "ILE", "LEU", "LYS", "MET", "PHE", "PRO", "SER", "THR", "TRP", "TYR", "VAL"], "entity_id": "1", "entry_id": "1AJ0", "rcsb_id": "1AJ0_1", "uniprot_ids": ["P0AC13"], "reference_sequence_identifiers": [{"database_accession": "P0AC13", "database_name": "UniProt", "entity_sequence_coverage": 1.0, "provenance_source": "SIFTS", "reference_sequence_coverage": 1.0}]}, "rcsb_polymer_entity_feature": [{"assignment_version": "34.0", "feature_id": "PF00809", "name": "Pterin binding enzyme (Pterin_bind)", "provenance_source": "Pfam", "type": "Pfam", "feature_positions": [{"beg_seq_id": 18, "end_seq_id": 257}]}, {"name": "Hydropathy values", "provenance_source": "biojava-7.2.4", "type": "hydropathy", "feature_positions": [{"beg_seq_id": 5, "values": [0.11, 0.32, 0.37, 0.37, -0.03, -0.59, -0.38, -0.69, -0.14, 0.16, -0.31, 0.58, 0.58, 0.28, 1.1, 1.2, 1.38, 0.52, 0.22, 0.58, -0.01, -0.82, -0.48, -0.99, -0.99, -1.17, -1.17, -1.17, -1.06, -0.47, -0.47, -0.22, 0.29, -0.07, -0.07, 0.52, 0.22, 0.22, -0.07, 0.82, 0.23, -0.03, 0.36, 0.91, 0.63, 1.52, 1.6, 1.0, 0.97, 1.31, 1.07, 0.72, 0.43, 0.43, -0.57, -1.24, -0.9, -1.17, -0.92, -1.27, -0.41, -0.41, 0.13, 0.24, 0.03, -0.31, -0.09, -0.68, -0.79, -0.79, -0.2, -0.84, 0.01, 0.87, 0.87, 0.64, 1.53, 2.23, 1.38, 0.38, 0.87, 0.01, 0.01, 0.3, 0.6, 0.01, 0.28, 0.28, 0.7, 0.3, 0.26, -0.39, -0.68, -0.71, -0.12, -1.09, -1.09, -1.1, -0.81, -0.81, -0.17, 0.18, -0.09, -0.94, 0.06, 0.94, 0.64, 0.06, 0.99, 0.02, -0.02, 0.2, 0.47, -0.42, -1.1, -0.76, -0.17, -0.24, -0.13, 0.16, -0.07, 0.22, 0.22, 0.32, 0.32, 0.54, -0.06, 0.8, 0.88, 1.1, 1.11, 1.14, 1.43, 1.09, 0.62, 0.41, -0.23, -0.94, -1.44, -1.44, -1.48, -2.08, -1.49, -1.62, -1.67, -1.63, -1.59, -1.9, -1.64, -0.94, -0.36, -0.94, -0.3, -0.26, -0.61, -0.37, 0.33, 0.37, -0.33, -0.92, -0.03, -0.3, -0.41, 0.37, 0.12, -0.58, -0.88, -0.53, 0.36, 0.06, -0.58, -0.47, -1.18, -0.37, 0.44, 0.67, 0.32, -0.36, -0.6, 0.14, 0.49, 1.23, 0.77, -0.09, -0.9, -0.09, 0.0, -0.31, -1.01, -1.11, -1.51, -1.04, -0.19, 0.4, -0.52, -0.01, 0.54, 0.54, 1.0, 0.73, -0.04, -0.16, -0.74, 0.18, -0.42, -0.2, 0.61, 0.77, 1.08, 1.64, 1.24, 1.13, 0.28, 0.37, 0.16, 0.23, -0.28, -0.62, -0.41, 0.1, 0.21, 1.11, 1.16, 0.77, 0.18, -0.17, -0.28, -0.28, -0.79, -0.44, -1.0, -0.53, -0.16, 0.21, 0.8, 1.77, 1.84, 2.13, 2.38, 2.68, 1.87, 1.62, 1.54, 0.99, 1.02, 1.02, 0.32, 0.59, 0.02, 0.02, 0.53, -0.1, -0.13, -0.71, -0.74, -0.63, -0.9, -0.33, -0.44, -0.44, 0.46, 0.46, 0.73, 0.19, 1.0, 0.71, 0.7, 0.77, -0.09, -0.94, -0.99, -1.69, -1.76, -2.57]}]}, {"name": "Disordered binding sites", "provenance_source": "Anchor2", "type": "disorder_binding", "feature_positions": [{"beg_seq_id": 1, "values": [0.36, 0.37, 0.38, 0.38, 0.39, 0.39, 0.4, 0.4, 0.4, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.42, 0.42, 0.42, 0.42, 0.42, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.42, 0.42, 0.42, 0.43, 0.43, 0.43, 0.42, 0.43, 0.43, 0.42, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.42, 0.42, 0.42, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.41, 0.4, 0.4, 0.39, 0.39, 0.38, 0.37, 0.37, 0.36, 0.36, 0.36, 0.36, 0.36, 0.37, 0.37, 0.38, 0.4, 0.41, 0.42, 0.43, 0.41, 0.4, 0.38, 0.37, 0.36, 0.35, 0.35, 0.36, 0.37, 0.38, 0.39, 0.41, 0.43, 0.42, 0.4, 0.39, 0.38, 0.38, 0.39, 0.39, 0.4, 0.4, 0.41, 0.43, 0.43, 0.42, 0.42, 0.42, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.43, 0.42, 0.42, 0.42, 0.42, 0.42, 0.42, 0.42, 0.43, 0.43, 0.43, 0.42, 0.41, 0.4, 0.39, 0.39, 0.39, 0.38, 0.37, 0.38, 0.39, 0.41, 0.42, 0.43, 0.42, 0.41, 0.4, 0.4, 0.4, 0.39, 0.39, 0.4, 0.4, 0.41, 0.42, 0.43, 0.43, 0.43, 0.43, 0.42, 0.41, 0.39, 0.38, 0.37, 0.36, 0.33, 0.31, 0.29, 0.26, 0.25, 0.23, 0.22, 0.22, 0.22, 0.21, 0.21, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.26, 0.24, 0.23, 0.22, 0.2, 0.19, 0.17, 0.16, 0.16, 0.15, 0.15, 0.14, 0.14, 0.15, 0.15, 0.15, 0.16, 0.17, 0.18, 0.19, 0.19, 0.2, 0.21, 0.22, 0.22, 0.23, 0.23, 0.22, 0.22, 0.21, 0.21, 0.2, 0.19, 0.19, 0.18, 0.18, 0.18, 0.17, 0.17, 0.16, 0.16, 0.15, 0.16, 0.16, 0.17, 0.17, 0.17, 0.17, 0.18, 0.2, 0.22, 0.24, 0.25, 0.26, 0.26, 0.27, 0.29, 0.29, 0.3, 0.3, 0.3, 0.3, 0.3, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.36, 0.37, 0.38, 0.39, 0.4, 0.4, 0.4, 0.4, 0.4, 0.39, 0.39, 0.4, 0.41, 0.41, 0.41, 0.4, 0.4, 0.39, 0.38, 0.38, 0.37, 0.36, 0.34, 0.32, 0.31, 0.3, 0.3, 0.3, 0.3, 0.29]}]}, {"name": "Disordered regions", "provenance_source": "IUPred2(short)", "type": "disorder", "feature_positions": [{"beg_seq_id": 1, "values": [0.82, 0.71, 0.68, 0.64, 0.63, 0.58, 0.49, 0.41, 0.38, 0.27, 0.16, 0.2, 0.15, 0.2, 0.32, 0.35, 0.33, 0.24, 0.24, 0.25, 0.32, 0.31, 0.38, 0.38, 0.38, 0.35, 0.28, 0.27, 0.31, 0.28, 0.29, 0.36, 0.36, 0.39, 0.39, 0.3, 0.27, 0.2, 0.3, 0.27, 0.27, 0.24, 0.24, 0.18, 0.13, 0.13, 0.1, 0.14, 0.2, 0.21, 0.24, 0.3, 0.29, 0.32, 0.35, 0.32, 0.36, 0.4, 0.39, 0.39, 0.35, 0.36, 0.4, 0.41, 0.41, 0.48, 0.45, 0.45, 0.37, 0.39, 0.32, 0.26, 0.26, 0.25, 0.16, 0.14, 0.17, 0.18, 0.1, 0.16, 0.11, 0.11, 0.06, 0.05, 0.03, 0.06, 0.05, 0.06, 0.09, 0.16, 0.15, 0.14, 0.12, 0.11, 0.13, 0.19, 0.18, 0.17, 0.13, 0.21, 0.18, 0.24, 0.24, 0.25, 0.24, 0.33, 0.24, 0.23, 0.23, 0.18, 0.16, 0.17, 0.25, 0.34, 0.32, 0.24, 0.26, 0.26, 0.25, 0.29, 0.3, 0.32, 0.32, 0.33, 0.43, 0.37, 0.3, 0.31, 0.28, 0.27, 0.3, 0.31, 0.3, 0.27, 0.3, 0.31, 0.38, 0.33, 0.36, 0.4, 0.39, 0.4, 0.4, 0.31, 0.4, 0.38, 0.38, 0.37, 0.4, 0.44, 0.37, 0.41, 0.4, 0.32, 0.25, 0.16, 0.17, 0.18, 0.16, 0.13, 0.12, 0.09, 0.08, 0.09, 0.12, 0.11, 0.06, 0.06, 0.1, 0.13, 0.13, 0.11, 0.06, 0.04, 0.06, 0.12, 0.17, 0.09, 0.08, 0.06, 0.08, 0.08, 0.13, 0.06, 0.06, 0.07, 0.07, 0.07, 0.09, 0.05, 0.03, 0.02, 0.04, 0.04, 0.05, 0.06, 0.02, 0.02, 0.04, 0.02, 0.04, 0.03, 0.03, 0.02, 0.02, 0.01, 0.01, 0.01, 0.02, 0.02, 0.03, 0.06, 0.06, 0.03, 0.05, 0.07, 0.04, 0.05, 0.05, 0.03, 0.05, 0.06, 0.12, 0.11, 0.17, 0.17, 0.23, 0.23, 0.28, 0.2, 0.17, 0.12, 0.1, 0.09, 0.1, 0.08, 0.06, 0.08, 0.14, 0.14, 0.17, 0.18, 0.1, 0.06, 0.06, 0.04, 0.07, 0.07, 0.05, 0.05, 0.09, 0.11, 0.1, 0.13, 0.15, 0.18, 0.21, 0.19, 0.17, 0.17, 0.15, 0.18, 0.12, 0.19, 0.23, 0.23, 0.29, 0.28, 0.27, 0.32, 0.25, 0.24, 0.29, 0.39, 0.43, 0.5, 0.58, 0.63, 0.71, 0.81, 0.84, 0.89]}]}], "rcsb_polymer_entity_feature_summary": [{"count": 1, "coverage": 0.85106, "type": "Pfam"}], "rcsb_polymer_entity_group_membership": [{"aggregation_method": "sequence_identity", "group_id": "4939_70", "similarity_cutoff": 70.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 189, "ref_beg_seq_id": 16}, {"entity_beg_seq_id": 190, "length": 93, "ref_beg_seq_id": 207}]}, {"aggregation_method": "sequence_identity", "group_id": "4718_90", "similarity_cutoff": 90.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 189, "ref_beg_seq_id": 16}, {"entity_beg_seq_id": 190, "length": 93, "ref_beg_seq_id": 207}]}, {"aggregation_method": "sequence_identity", "group_id": "3858_100", "similarity_cutoff": 100.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 282, "ref_beg_seq_id": 3}]}, {"aggregation_method": "sequence_identity", "group_id": "4592_30", "similarity_cutoff": 30.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 12, "ref_beg_seq_id": 314}, {"entity_beg_seq_id": 13, "length": 25, "ref_beg_seq_id": 327}, {"entity_beg_seq_id": 38, "length": 37, "ref_beg_seq_id": 353}, {"entity_beg_seq_id": 75, "length": 15, "ref_beg_seq_id": 391}, {"entity_beg_seq_id": 90, "length": 22, "ref_beg_seq_id": 409}, {"entity_beg_seq_id": 112, "length": 10, "ref_beg_seq_id": 432}, {"entity_beg_seq_id": 122, "length": 8, "ref_beg_seq_id": 443}, {"entity_beg_seq_id": 130, "length": 21, "ref_beg_seq_id": 452}, {"entity_beg_seq_id": 151, "length": 1, "ref_beg_seq_id": 474}, {"entity_beg_seq_id": 152, "length": 4, "ref_beg_seq_id": 476}, {"entity_beg_seq_id": 156, "length": 34, "ref_beg_seq_id": 481}, {"entity_beg_seq_id": 190, "length": 18, "ref_beg_seq_id": 517}, {"entity_beg_seq_id": 208, "length": 23, "ref_beg_seq_id": 544}, {"entity_beg_seq_id": 231, "length": 52, "ref_beg_seq_id": 568}]}, {"aggregation_method": "sequence_identity", "group_id": "4785_95", "similarity_cutoff": 95.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 282, "ref_beg_seq_id": 16}]}, {"aggregation_method": "sequence_identity", "group_id": "5928_50", "similarity_cutoff": 50.0, "aligned_regions": [{"entity_beg_seq_id": 1, "length": 189, "ref_beg_seq_id": 16}, {"entity_beg_seq_id": 190, "length": 93, "ref_beg_seq_id": 207}]}, {"aggregation_method": "matching_uniprot_accession", "group_id": "P0AC13", "aligned_regions": [{"entity_beg_seq_id": 1, "length": 282, "ref_beg_seq_id": 1}]}], "rcsb_polymer_entity_name_com": [{"name": "DHPS"}], "rcsb_related_target_references": [{"related_resource_name": "ChEMBL", "related_resource_version": "36", "related_target_id": "CHEMBL2364668", "target_taxonomy_id": 83333, "aligned_target": [{"entity_beg_seq_id": 1, "length": 281, "target_beg_seq_id": 1}]}, {"related_resource_name": "ChEMBL", "related_resource_version": "36", "related_target_id": "CHEMBL4032", "target_taxonomy_id": 83333, "aligned_target": [{"entity_beg_seq_id": 1, "length": 281, "target_beg_seq_id": 1}]}, {"related_resource_name": "DrugBank", "related_resource_version": "5.1", "related_target_id": "P0AC13", "target_taxonomy_id": 83333, "aligned_target": [{"entity_beg_seq_id": 1, "length": 281, "target_beg_seq_id": 1}]}], "rcsb_target_cofactors": [{"binding_assay_value": 3.12, "binding_assay_value_type": "pKd", "cofactor_in_ch_ikey": "JHEKNTQSGTVPAO-UHFFFAOYSA-N", "cofactor_smiles": "Nc1nc2[nH]c(S)nc2c(=O)[nH]1", "cofactor_chem_comp_id": "B55", "cofactor_resource_id": "CHEMBL178006", "neighbor_flag": "N", "resource_name": "ChEMBL", "resource_version": "36", "target_resource_id": "CHEMBL2364668"}, {"binding_assay_value": 2.3, "binding_assay_value_type": "pIC50", "cofactor_in_ch_ikey": "XQCZBXHVTFVIFE-UHFFFAOYSA-N", "cofactor_smiles": "Nc1nccc(O)n1", "cofactor_resource_id": "CHEMBL56260", "neighbor_flag": "N", "resource_name": "ChEMBL", "resource_version": "36", "target_resource_id": "CHEMBL4032"}, {"cofactor_in_ch_ikey": "NDAYQJDHGXTBJL-MWWSRJDJSA-N", "cofactor_smiles": "CC(C)C[C@@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCCO", "cofactor_name": "Gramicidin D", "cofactor_resource_id": "DB00027", "mechanism_of_action": "Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization (it acts as a channel). This leads to (i) loss of intracellular solutes (e.g., K+ and amino acids); (ii) dissipation of the transmembrane potential; (iii) inhibition of respiration; (iv) a reduction in ATP pools; and (v) inhibition of DNA, RNA, and protein synthesis, which leads to cell death.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "DOAKLVKFURWEDJ-QCMAZARJSA-N", "cofactor_smiles": "CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O", "cofactor_name": "Daptomycin", "cofactor_resource_id": "DB00080", "mechanism_of_action": "The mechanism of action of daptomycin remains poorly understood. Studies have suggested a direct inhibition of cell membrane/cell wall constituent biosynthesis, including peptidoglycan, uridine diphosphate-N-acid, acetyl-L-alanine, and lipoteichoic acid (LTA). However, no convincing evidence has been presented for any of these models, and an effect on LTA biosynthesis has been ruled out by other studies in _S. aureus_ and _E. faecalis_.[A231384, A231394, A14171]\r\n\r\nIt is well understood that free daptomycin (apo-daptomycin) is a trianion at physiological pH, which binds Ca<sup>2+</sup> in a 1:1 stoichiometric ratio to become a monoanion, which is thought to rely primarily on the Asp(7), Asp(9), and L-3MeGlu12 residues that form a DXDG motif.[A231374, A231379, A231384] Calcium-binding facilitates daptomycin's insertion into bacterial membranes preferentially due to their high content of the acidic phospholipids phosphatidylglycerol (PG) and cardiolipin (CL), wherein it is proposed that daptomycin can bind two calcium equivalents and form oligomers.[A231379] PG is recognized as the main membrane requirement for daptomycin activity; daptomycin preferentially localizes in PG-rich membrane domains, and mutations affecting PG prevalence are linked to daptomycin resistance.[A231379] Calcium-dependent membrane binding is the generally accepted mechanism of action for daptomycin, but the precise downstream effects are unclear, and numerous models have been proposed.\r\n\r\nOne mechanism proposes that the daptomycin membrane binding alters membrane fluidity, causing dissociation of cell wall biosynthetic enzymes such as the lipid II synthase MurG and the phospholipid synthase PlsX.[A231384] This is consistent with the observed effects of daptomycin on cell shape in various bacteria at concentrations at or above the minimum inhibitory concentration (MIC).[A14171] Aberrant cell morphology is also consistent with the observed localization of daptomycin at the division septa and a hypothesized role in inhibiting cell division.[A231379] A recent study suggested the formation of tripartite complexes containing calcium-bound daptomycin, PG, and various undecaprenyl-coupled cell envelope precursors, which subsequently include lipid II. This complex is proposed to inhibit cell division, lead to the dispersion of cell wall biosynthetic machinery, and eventually cause lysis of the membrane bilayer at the septum causing cell death.[A231384, A231409]\r\n\r\nAnother popular model is based on early observations that daptomycin, in a calcium-dependent manner, caused potassium ion leakage and loss of membrane potential in treated bacterial cells.[A231394, A231419, A231424] Although this lead some to suggest that daptomycin could bind PG to form oligomeric pores in the bacterial membrane,[A231384] no cell lysis was observed in _S. aureus_ or _E. faecalis_,[A231379] and the daptomycin-induced ion conduction is inconsistent with pore formation.[A231429] Rather, it has been proposed that daptomycin forms calcium-dependent dimeric complexes in fixed ratios of Dap<sub>2</sub>Ca<sub>3</sub>PG<sub>2</sub>, which can act as transient ionophores.[A231429] The observed loss of membrane potential is suggested to result in a non-specific loss of gradient-dependent nutrient transport, ATP production, and biosynthesis, leading to cell death.[A231379, A231424]\r\n\r\nNotably, these models are not strictly mutually exclusive and are supported to varying extents by observed resistance mutations. The strict requirement for PG for daptomycin bactericidal action is supported by mutations in _mprF_, _cls2_, _pgsA_, and the _dlt_ operon in _S. aureus_, _cls_ in various enterococci, and _pgsA_, PG synthase, and the _dlt_ operon in _E. faecium_, all of which alter the bacterial membrane composition and specifically the PG content of bacterial membranes. Other noted mutations in various regulatory systems that control membrane homeostasis also support the cell membrane as the site of daptomycin action. Curiously, in _E. faecalis_, the most commonly observed form of daptomycin resistance is characterized by abnormal division septa, which supports the cell division-based mechanism of daptomycin action.[A231379, A231384]", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "FDDDEECHVMSUSB-UHFFFAOYSA-N", "cofactor_smiles": "NC1=CC=C(C=C1)S(N)(=O)=O", "cofactor_chem_comp_id": "SAN", "cofactor_name": "Sulfanilamide", "cofactor_resource_id": "DB00259", "mechanism_of_action": "Sulfanilamide is a competitive inhibitor of bacterial enzyme dihydropteroate synthetase. This enzyme normally uses para-aminobenzoic acid (PABA) for synthesizing the necessary folic acid. The inhibited reaction is normally necessary in these organisms for the synthesis of folic acid. Without it, bacteria cannot replicate.", "neighbor_flag": "Y", "pubmed_ids": [16487326, 16997145, 9127492], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "NHUHCSRWZMLRLA-UHFFFAOYSA-N", "cofactor_smiles": "CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C", "cofactor_name": "Sulfisoxazole", "cofactor_resource_id": "DB00263", "mechanism_of_action": "Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.", "neighbor_flag": "N", "pubmed_ids": [16000430, 15673729, 7486915, 37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "SEEPANYCNGTZFQ-UHFFFAOYSA-N", "cofactor_smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=N1", "cofactor_name": "Sulfadiazine", "cofactor_resource_id": "DB00359", "mechanism_of_action": "Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "VACCAVUAMIDAGB-UHFFFAOYSA-N", "cofactor_smiles": "CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1", "cofactor_name": "Sulfamethizole", "cofactor_resource_id": "DB00576", "mechanism_of_action": "Sulfamethizole is a competitive inhibitor of bacterial enzyme dihydropteroate synthetase. The normal para-aminobenzoic acid (PABA) substrate is prevented from binding. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.", "neighbor_flag": "N", "pubmed_ids": [2372557, 37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "SKIVFJLNDNKQPD-UHFFFAOYSA-N", "cofactor_smiles": "CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1", "cofactor_name": "Sulfacetamide", "cofactor_resource_id": "DB00634", "mechanism_of_action": "Sulfacetamide is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), an essential component for bacterial growth (according to the Woods-Fildes theory). The inhibited reaction is necessary in these organisms for the synthesis of folic acid.", "neighbor_flag": "N", "pubmed_ids": [19434845, 13873645, 14700578], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "KXRZBTAEDBELFD-UHFFFAOYSA-N", "cofactor_smiles": "COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1", "cofactor_name": "Sulfametopyrazine", "cofactor_resource_id": "DB00664", "mechanism_of_action": "Sulfametopyrazine is a competitive inhibitor of the bacterial  enzyme dihydropteroate synthetase. Para-aminobenzoic acid (PABA), a substrate of the enzyme is prevented  from binding. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_name": "Colistin", "cofactor_resource_id": "DB00803", "mechanism_of_action": "Colistin is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistin is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "GECHUMIMRBOMGK-UHFFFAOYSA-N", "cofactor_smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1", "cofactor_chem_comp_id": "SFY", "cofactor_name": "Sulfapyridine", "cofactor_resource_id": "DB00891", "mechanism_of_action": "Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid by means of processing the substrate para-aminobenzoic acid (PABA). Dihydropteroate synthetase activity is vital in the synthesis of folate, and folate is required for cells to make nucleic acids, such as DNA or RNA. So if DNA molecules cannot be built, the cell cannot divide.\r\n", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "JLKIGFTWXXRPMT-UHFFFAOYSA-N", "cofactor_smiles": "CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1", "cofactor_chem_comp_id": "08D", "cofactor_name": "Sulfamethoxazole", "cofactor_resource_id": "DB01015", "mechanism_of_action": "Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolic acid synthesis due to its structural similarity to an endogenous substrate, para-aminobenzoic acid (PABA).[A187343,A187364] Most bacteria meet their need for folic acid by synthesizing it from PABA, as opposed to Animalia that require exogenous folic acid sources.[L11851] Sulfamethoxazole competitively inhibits dihydropteroate synthase, the enzyme responsible for bacterial conversion of PABA to dihydrofolic acid.[A112882] Inhibition of this pathway prevents the synthesis of tetrahydrofolate and, ultimately, the synthesis of bacterial purines and DNA, resulting in a bacteriostatic effect.[A187340]", "neighbor_flag": "N", "pubmed_ids": [1093654], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "BSSIRFLGSWHWDE-UHFFFAOYSA-I", "cofactor_smiles": "CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O", "cofactor_name": "Colistimethate", "cofactor_resource_id": "DB01111", "mechanism_of_action": "Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "SIBQAECNSSQUOD-UHFFFAOYSA-N", "cofactor_smiles": "CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O", "cofactor_name": "Sulfacytine", "cofactor_resource_id": "DB01298", "mechanism_of_action": "Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.", "neighbor_flag": "N", "pubmed_ids": [1195474, 37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "PJSFRIWCGOHTNF-UHFFFAOYSA-N", "cofactor_smiles": "COC1=NC=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1OC", "cofactor_name": "Sulfadoxine", "cofactor_resource_id": "DB01299", "mechanism_of_action": "Sulfadoxine is a sulfa drug, often used in combination with pyrimethamine  to treat malaria. This medicine may also be used to prevent malaria in people who are living in, or will be traveling to, an area where there is a chance of getting malaria. Sulfadoxine targets Plasmodium dihydropteroate synthase and dihydrofolate reductase.  Sulfa drugs or Sulfonamides are antimetabolites.  They compete with para-aminobenzoic acid (PABA) for incorporation into folic acid. The action of sulfonamides exploits the difference between mammal cells and other kinds of cells in their folic acid metabolism. All cells require folic acid for growth. Folic acid (as a vitamin) diffuses or is transported into human cells. However, folic acid cannot cross bacterial (and certain protozoan) cell walls by diffusion or active transport. For this reason bacteria must synthesize folic acid from p-aminobenzoic acid.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "QPPBRPIAZZHUNT-UHFFFAOYSA-N", "cofactor_smiles": "CC1=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC=C1", "cofactor_name": "Sulfamerazine", "cofactor_resource_id": "DB01581", "mechanism_of_action": "Sulfamerazine is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamerazine is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA. ", "neighbor_flag": "N", "pubmed_ids": [7486915, 21084778, 4577373, 37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "ASWVTGNCAZCNNR-UHFFFAOYSA-N", "cofactor_smiles": "CC1=CC(C)=NC(NS(=O)(=O)C2=CC=C(N)C=C2)=N1", "cofactor_name": "Sulfamethazine", "cofactor_resource_id": "DB01582", "mechanism_of_action": "Sulfonamides inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth. Pyrimethamine and trimethoprim inhibit dihydrofolate reductase, another step in THF synthesis, and therefore act synergistically with the sulfonamides.", "neighbor_flag": "N", "pubmed_ids": [7486915, 21084778, 4577373, 37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "AJXFJEHKGGCFNM-UHFFFAOYSA-N", "cofactor_smiles": "NC1=NC2=NC=C(COP(O)(O)=O)N=C2C(=O)N1", "cofactor_chem_comp_id": "PMM", "cofactor_name": "Pterin-6-Yl-Methyl-Monophosphate", "cofactor_resource_id": "DB03592", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "NMCMUSAXKISTKW-UHFFFAOYSA-N", "cofactor_smiles": "CNC1=C(C(=O)NC(N)=N1)[N+]([O-])=O", "cofactor_chem_comp_id": "680", "cofactor_name": "6-Methylamino-5-Nitroisocytosine", "cofactor_resource_id": "DB03705", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "AMDUVUKDRBIVAH-UHFFFAOYSA-N", "cofactor_smiles": "[H]N([H])C1=NC(=O)C2=NC(COP(O)(=O)OP(O)(O)=O)=CN=C2N1[H]", "cofactor_chem_comp_id": "HH2", "cofactor_name": "6-hydroxymethylpterin diphosphate", "cofactor_resource_id": "DB04047", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "JOAQINSXLLMRCV-UHFFFAOYSA-N", "cofactor_smiles": "NC1=NC2=NC=C(CNC3=CC=C(C=C3)C(O)=O)N=C2C(=O)N1", "cofactor_chem_comp_id": "PT1", "cofactor_name": "Pteroic acid", "cofactor_resource_id": "DB04196", "neighbor_flag": "Y", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "VHFGEBVPHAGQPI-LXKZPTCJSA-N", "cofactor_smiles": "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2", "cofactor_name": "Oritavancin", "cofactor_resource_id": "DB04911", "mechanism_of_action": "The cell wall is vital for the survival and replication of bacteria, making it a primary target for antibiotic therapy.[A193428] Oritavancin works against susceptible gram-positive organisms via three separate mechanisms. Firstly, it binds to the stem peptide of peptidoglycan precursors, inhibiting transglycosylation (polymerization). This process normally occurs during cell wall synthesis. Secondly, oritavancin inhibits crosslinking during bacterial cell wall biosynthesis via binding to cell wall pentaglycyl peptide bridging segments. Finally, this drug also acts by disrupting the bacterial cell membrane, interfering with its integrity, which eventually leads to cell death by various mechanisms.[A193416,A193425,L8492]", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "UEJSSZHHYBHCEL-UHFFFAOYSA-N", "cofactor_smiles": "[Ag+].NC1=CC=C(C=C1)S(=O)(=O)[N-]C1=NC=CC=N1", "cofactor_name": "Silver sulfadiazine", "cofactor_resource_id": "DB05245", "mechanism_of_action": "Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. A specific mechanism of action has not been determined, but silver sulfadiazine's effectiveness may possibly be from a synergistic interaction, or the action of each component. Silver is a biocide, which binds to a broad range of targets. Silver ions bind to nucleophilic amino acids, as well as sulfhydryl, amino, imidazole, phosphate, and carboxyl groups in proteins, causing protein denaturation and enzyme inhibition. \r\nSilver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death. \r\nSulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "AVAACINZEOAHHE-VFZPANTDSA-N", "cofactor_smiles": "[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O", "cofactor_chem_comp_id": "O6P", "cofactor_name": "Doripenem", "cofactor_resource_id": "DB06211", "mechanism_of_action": "Doripenem is a broad-spectrum carbapenem antibiotic with activity against many gram-positive and gram-negative aerobic bacteria, as well as a variety of anaerobes. Like other beta-lactam antibiotics, doripenem's bactericidal mechanism of action is mostly due to cell death after inhibition of bacterial enzymes called penicillin-bindng proteins (PBPs), which are responsible for peptidoglycan cross-linking during the synthesis of the bacterial cell wall. Carbapenems mainly have high affinity for PBPs 1a, 1b, 2 and 3. Inhibition of each PBP usually results in a different inactivating mechanism. Inhibition of PBPs 1a and 1b results in fast bacterial killing through the formation of spheroplasts, inhibition of PBP 2 results in rod-shaped bacteria to become spherical, and inhibition of PBP 3 results in filamentous-shaped organisms. The PBPs preferentially bound by different carbapenems depend on the organism. In E.coli and P.aeruginosa, doripenem binds to PBP\r\n2, which is involved in the maintenance of cell shape, as well as to PBPs 3 and 4. Doripenem has a 1-beta-methyl side chain, which allows it to be relatively resistant to dehydropeptidase, as well as a trans-alpha-1-hydroxyethyl group at position 6 which provides beta-lactamase resistance. Like other carbapenems, doripenem is different from most beta-lactams due to its stability against hydrolysis by most beta-lactamases, including penicillinases, cephalosporinases, ESBL, and Amp-C producing enterobacteriaceae.", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "QWCJHSGMANYXCW-UHFFFAOYSA-N", "cofactor_smiles": "NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1", "cofactor_name": "Sulfaphenazole", "cofactor_resource_id": "DB06729", "mechanism_of_action": "Sulfaphenazole is a sulfonamide antibacterial. In bacteria, antibacterial sulfonamides act as competitive inhibitors of the enzyme dihydropteroate synthetase (DHPS), an enzyme involved in folate synthesis. As such, the microorganism will be \"starved\" of folate and die.", "neighbor_flag": "N", "pubmed_ids": [7486915], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "GPTONYMQFTZPKC-UHFFFAOYSA-N", "cofactor_smiles": "COC1=CN=C(NS(=O)(=O)C2=CC=C(N)C=C2)N=C1", "cofactor_name": "Sulfameter", "cofactor_resource_id": "DB06821", "neighbor_flag": "N", "pubmed_ids": [23118736], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "HGGAKXAHAYOLDJ-FHZUQPTBSA-N", "cofactor_smiles": "[H][C@]12SC([C@H]3CCCO3)=C(N1C(=O)[C@@H]2[C@@H](C)O)C(O)=O", "cofactor_chem_comp_id": "FPM", "cofactor_name": "Faropenem", "cofactor_resource_id": "DB12190", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "QDUIJCOKQCCXQY-WHJQOFBOSA-N", "cofactor_smiles": "[H][C@]12SCC(C[N+]3=C4C=CC=NN4C=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\\C1=NSC(N)=N1)C([O-])=O", "cofactor_name": "Cefozopran", "cofactor_resource_id": "DB13667", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "BRBKOPJOKNSWSG-UHFFFAOYSA-N", "cofactor_smiles": "NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1", "cofactor_chem_comp_id": "QA9", "cofactor_name": "Sulfaguanidine", "cofactor_resource_id": "DB13726", "mechanism_of_action": "Sulfaguanidine is a sulfonamide antibacterial that inhibits dihydropteroate synthase (DHPS) by acting as a PABA analogue, blocking folate biosynthesis in susceptible microbes.[A65653]", "neighbor_flag": "N", "pubmed_ids": [9187658], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "JFNWFXVFBDDWCX-UHFFFAOYSA-N", "cofactor_smiles": "CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1", "cofactor_name": "Acetyl sulfisoxazole", "cofactor_resource_id": "DB14033", "mechanism_of_action": "Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid [L2798].", "neighbor_flag": "N", "pubmed_ids": [16000430, 15673729, 7486915], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_in_ch_ikey": "PIICEJLVQHRZGT-UHFFFAOYSA-N", "cofactor_smiles": "NCCN", "cofactor_chem_comp_id": "EDN", "cofactor_name": "Ethylenediamine", "cofactor_resource_id": "DB14189", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}, {"cofactor_name": "Polymyxin B", "cofactor_resource_id": "DB00781", "mechanism_of_action": "The alpha and gamma diaminobutyric acid of a positively charged polymyxin B forms an electrostatic interaction with the phosphate groups of a negatively charged lipid A on the outer membrane of a Gram negative bacterium[A176426]. Calcium and Magnesium ions are displaced from phosphates of the membrane lipids, destabalising the lipopolysaccharide (LPS), increasing membrane permeability, causing cytoplasmic leaking, and killing the cell[A176426].\r\n\r\nPolymyxin B can also bind and neutralize LPS released during bacterial lysis, preventing reactions to endotoxin[A176426].\r\n\r\nA third activity of polymyxin B is the inhibition of type II NADH-quinone oxidoreductases in the bacterial inner membrane, which are essential for respiration[A176426].\r\n\r\nPolymyxin is active against common Gram negative bacteria but not Gram negative cocci, Gram positive bacteria, or anaerobic bacteria[A176426].", "neighbor_flag": "N", "pubmed_ids": [37713619], "resource_name": "DrugBank", "resource_version": "5.1", "target_resource_id": "P0AC13"}], "rcsb_id": "1AJ0_1"}